{"id":407332,"date":"2021-01-04T07:33:28","date_gmt":"2021-01-04T12:33:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407332"},"modified":"2021-01-04T07:33:28","modified_gmt":"2021-01-04T12:33:28","slug":"zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/","title":{"rendered":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DEVON, Pa., Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will participate in two upcoming virtual investor conferences. Mr. Anido will participate in a fireside chat during the <strong>H.C. Wainwright BioConnect Conference<\/strong> which will be available on demand January 11-14, 2021. He will also present a company overview during the <strong>ICR Conference 2021<\/strong> on Thursday, January 14, 2021 at 10:00 a.m.\u00a0ET.<\/p>\n<p>Investors interested in arranging a virtual meeting with the Company\u2019s management during the ICR Conference 2021 should contact the conference coordinator or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gcAC3g5IvJ0k1_SBVO_wgVoxcNddix4bPYWyykom8F0LZO90KTFB33yNWjJXECyRcW5cPVExt0_qNHLDXc3efTG87n3bx5wDudPQGFhNSquzO1lwYmnVVAexNySMo3hQ\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">brandon.weiner@westwicke.com<\/a>. Webcasts of both conferences will be accessible under the Events &amp; Webcasts tab of the Investor section of Zynerba\u2019s website at www.zynerba.com.<\/p>\n<p>\n        <strong>About Zynerba Pharmaceuticals, Inc. <\/strong><br \/>\n        <br \/>Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l1HWRtx_C0Cb4_uD7CNRtYSkvJQM0gS-o_KQuZXADOkEkrMKtc_V_G5lHIvodwgDjBoXtjGClsMF-Ct5DjS8nw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.zynerba.com<\/a> and follow us on Twitter at @ZynerbaPharma.\u00a0\u00a0<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. These and other risks are described in the Company\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ADvzt8S8HnmW4q_Kp_Z45n1M4K1mm3tkp5GwJcA0ecevjKxlcM7s-vEVHuh_9Co1BeV1cORtpozWKpJex6TYDw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.sec.gov<\/a>. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>Westwicke, an ICR Company <br \/>Office: 443-213-0505<br \/>Cell: 443-377-4767<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rdhCWrFwBDFR9FOOOnLGsK8W7EqA3cevMaeJfvazc4QdI4gV7716-sJec3PtOs2bvl11nN30ifW8CZALWVIJsSLz-5Dvh9pr8qcDV8aZUno=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">peter.vozzo@westwicke.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9c032673-4996-4404-8f25-300533712a61\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will participate in two upcoming virtual investor conferences. Mr. Anido will participate in a fireside chat during the H.C. Wainwright BioConnect Conference which will be available on demand January 11-14, 2021. He will also present a company overview during the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m.\u00a0ET. Investors interested in arranging a virtual meeting with the Company\u2019s management during the ICR Conference 2021 should contact the conference coordinator or brandon.weiner@westwicke.com. Webcasts of both conferences will be accessible under the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407332","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will participate in two upcoming virtual investor conferences. Mr. Anido will participate in a fireside chat during the H.C. Wainwright BioConnect Conference which will be available on demand January 11-14, 2021. He will also present a company overview during the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m.\u00a0ET. Investors interested in arranging a virtual meeting with the Company\u2019s management during the ICR Conference 2021 should contact the conference coordinator or brandon.weiner@westwicke.com. Webcasts of both conferences will be accessible under the &hellip; Continue reading &quot;Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:33:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences\",\"datePublished\":\"2021-01-04T12:33:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/\"},\"wordCount\":421,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/\",\"name\":\"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\",\"datePublished\":\"2021-01-04T12:33:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk","og_description":"DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will participate in two upcoming virtual investor conferences. Mr. Anido will participate in a fireside chat during the H.C. Wainwright BioConnect Conference which will be available on demand January 11-14, 2021. He will also present a company overview during the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m.\u00a0ET. Investors interested in arranging a virtual meeting with the Company\u2019s management during the ICR Conference 2021 should contact the conference coordinator or brandon.weiner@westwicke.com. Webcasts of both conferences will be accessible under the &hellip; Continue reading \"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:33:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences","datePublished":"2021-01-04T12:33:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/"},"wordCount":421,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/","name":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=","datePublished":"2021-01-04T12:33:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NiMzOTAyMzQ4IzIwMTcyOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-to-present-at-two-january-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407332"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}